Search

The article offers information on cycloset, a formulation of bromocriptine mesylate that is approved by the U.S. Food and Drug Administration for the treatment of adults with type two diabetes. It focuses on the benefits that include the once a day dosage, reduction of postprandial glucose level without increasing the concentration of plasma insulin and adherence to the cardiovascular safety guidelines in pharmacotherapy. It discusses the results of clinical trials on the efficacy and safety of cycloset.

The article reports on the approval by the U.S. Food and Drug Administration (FDA) of quick-release bromocriptine as a new formulation for the treatment of type 2 diabetes.

The article focuses on data presented at the 2007 American Diabetes Association annual meeting regarding quick-release bromocriptine, a dopamine receptor. Bromocriptine acts centrally in the brain to reset neuroendocrine signaling when given as a morning dose of up to 4.8 mg. According to the study, bromocriptine reduces the rate of major cardiovascular events in patients with type 2 diabetes compared with placebo. Results showed that the rate of serious adverse event was similar in the two treatment groups.